Pier 88 Investment Partners LLC Sells 5,710 Shares of Insulet Corporation $PODD

Pier 88 Investment Partners LLC lessened its stake in shares of Insulet Corporation (NASDAQ:PODD) by 86.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 900 shares of the medical instruments supplier’s stock after selling 5,710 shares during the quarter. Pier 88 Investment Partners LLC’s holdings in Insulet were worth $256,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of PODD. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 43 shares during the period. Quent Capital LLC bought a new position in shares of Insulet during the 3rd quarter worth approximately $49,000. Measured Wealth Private Client Group LLC bought a new position in shares of Insulet during the 3rd quarter worth approximately $49,000. Osterweis Capital Management Inc. bought a new position in shares of Insulet during the 2nd quarter worth approximately $51,000. Finally, Zions Bancorporation National Association UT lifted its position in shares of Insulet by 57.3% during the 3rd quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 63 shares during the period.

Analyst Ratings Changes

PODD has been the subject of several analyst reports. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Raymond James Financial cut their target price on Insulet from $355.00 to $263.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. cut their price objective on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, May 7th. Jefferies Financial Group cut their price objective on Insulet from $400.00 to $360.00 in a research report on Thursday, May 7th. Finally, Robert W. Baird cut their price objective on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Eighteen analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $257.09.

Insider Buying and Selling at Insulet

In other news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the transaction, the director directly owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.36% of the stock is currently owned by insiders.

Insulet Trading Up 0.0%

Shares of PODD opened at $154.17 on Tuesday. The stock has a fifty day moving average price of $207.40 and a two-hundred day moving average price of $261.40. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. Insulet Corporation has a 52-week low of $148.30 and a 52-week high of $354.88. The company has a market cap of $10.68 billion, a price-to-earnings ratio of 35.85, a PEG ratio of 1.25 and a beta of 1.20.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts predict that Insulet Corporation will post 6.43 EPS for the current fiscal year.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet was highlighted by Zacks as a top value stock for the long term, suggesting some investors still see attractive upside despite the recent pullback. Why Insulet (PODD) is a Top Value Stock for the Long-Term
• Positive Sentiment: The company announced a Middle East regional headquarters in Riyadh, a strategic expansion that could support international growth over time. Insulet establishes Middle East regional headquarters in Riyadh, marking a strategic milestone in the Kingdom
• Neutral Sentiment: Short interest data showed no meaningful change, with reported short interest at 0 shares, so this does not appear to be a driver of the stock move.
• Negative Sentiment: Several analysts lowered price targets for Insulet, including Jefferies, Citi, Stifel, Canaccord, Leerink, Raymond James, Baird, Oppenheimer, and Evercore, signaling softer near-term expectations and pressuring the stock. Jefferies Financial Group Cuts Insulet (NASDAQ:PODD) Price Target to $360.00

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.